Cited 8 times in
Impact of one-month DAPT followed by aspirin monotherapy in patients undergoing percutaneous coronary intervention according to clinical presentation: a post hoc analysis of the randomised One-Month DAPT trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김병극 | - |
dc.contributor.author | 안철민 | - |
dc.contributor.author | 이승준 | - |
dc.contributor.author | 홍명기 | - |
dc.contributor.author | 홍성진 | - |
dc.contributor.author | 이용준 | - |
dc.contributor.author | 김중선 | - |
dc.contributor.author | 고영국 | - |
dc.contributor.author | 최동훈 | - |
dc.date.accessioned | 2022-12-22T03:07:55Z | - |
dc.date.available | 2022-12-22T03:07:55Z | - |
dc.date.issued | 2022-08 | - |
dc.identifier.issn | 1774-024X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/191804 | - |
dc.description.abstract | Background: The impact of 1-month dual antiplatelet therapy (DAPT) followed by aspirin monotherapy according to clinical presentation has not been elucidated. Aims: This study aimed to compare the impact of 1-month DAPT followed by aspirin monotherapy after polymer-free drug-coated stent (PF-DCS) implantation (1-month DAPT after PF-DCS) vs 6-12-month DAPT followed by aspirin monotherapy after biodegradable polymer drug-eluting stent (BP-DES) implantation (6-12-month DAPT after BP-DES) according to clinical presentation. Methods: This is a post hoc analysis of the One-Month DAPT trial. The primary outcome was the composite of major adverse cardiac and cerebrovascular events (MACCE; a composite of cardiac death, non-fatal myocardial infarction, target vessel revascularisation, and stroke) and major bleeding. Results: Among 1,828 patients with stable coronary artery disease (CAD), 1-month DAPT after PF-DCS resulted in lower rates of the primary outcome than 6-12-month DAPT after BP-DES (3.9% vs 6.5%; hazard ratio [HR] 0.59, 95% confidence interval [CI]: 0.39-0.90; p=0.012). However, among 1,192 patients with acute coronary syndrome (ACS), the rates of the primary outcome were not significantly different between the two therapy groups (5.6% vs 3.6%; HR 1.57, 95% CI: 0.91-2.70; p=0.102) and a significant interaction was observed between therapy and clinical presentation regarding the primary outcome (Pint=0.005). A significant interaction was observed in MACCE (Pint=0.016), but not in major bleeding (Pint=0.276). Conclusions: In patients undergoing drug-eluting stent implantation for non-complex lesions, the benefits of 1-month DAPT followed by aspirin monotherapy for a composite of ischaemic and bleeding outcomes were found in patients with stable CAD, but not in those with ACS. Clinicaltrials: gov: NCT02513810. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Société Europa édition | - |
dc.relation.isPartOf | EUROINTERVENTION | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Acute Coronary Syndrome* / drug therapy | - |
dc.subject.MESH | Acute Coronary Syndrome* / surgery | - |
dc.subject.MESH | Aspirin / therapeutic use | - |
dc.subject.MESH | Clopidogrel / therapeutic use | - |
dc.subject.MESH | Coronary Artery Disease* / drug therapy | - |
dc.subject.MESH | Coronary Artery Disease* / surgery | - |
dc.subject.MESH | Drug Therapy, Combination | - |
dc.subject.MESH | Drug-Eluting Stents* | - |
dc.subject.MESH | Hemorrhage / etiology | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Percutaneous Coronary Intervention* / methods | - |
dc.subject.MESH | Platelet Aggregation Inhibitors / therapeutic use | - |
dc.subject.MESH | Ticlopidine / therapeutic use | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Impact of one-month DAPT followed by aspirin monotherapy in patients undergoing percutaneous coronary intervention according to clinical presentation: a post hoc analysis of the randomised One-Month DAPT trial | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Yong-Joon Lee | - |
dc.contributor.googleauthor | Jae Young Cho | - |
dc.contributor.googleauthor | Kyeong Ho Yun | - |
dc.contributor.googleauthor | Seung-Jun Lee | - |
dc.contributor.googleauthor | Sung-Jin Hong | - |
dc.contributor.googleauthor | Chul-Min Ahn | - |
dc.contributor.googleauthor | Byeong-Keuk Kim | - |
dc.contributor.googleauthor | Young-Guk Ko | - |
dc.contributor.googleauthor | Donghoon Choi | - |
dc.contributor.googleauthor | Myeong-Ki Hong | - |
dc.contributor.googleauthor | Yangsoo Jang | - |
dc.contributor.googleauthor | Jung-Sun Kim | - |
dc.identifier.doi | 10.4244/EIJ-D-22-00135 | - |
dc.contributor.localId | A00493 | - |
dc.contributor.localId | A02269 | - |
dc.contributor.localId | A02927 | - |
dc.contributor.localId | A04391 | - |
dc.contributor.localId | A04403 | - |
dc.contributor.localId | A02984 | - |
dc.contributor.localId | A00961 | - |
dc.contributor.localId | A00127 | - |
dc.contributor.localId | A04053 | - |
dc.relation.journalcode | J00800 | - |
dc.identifier.eissn | 1969-6213 | - |
dc.identifier.pmid | 35470799 | - |
dc.identifier.url | https://eurointervention.pcronline.com/article/impact-of-one-month-dapt-followed-by-aspirin-monotherapy-in-patients-undergoing-percutaneous-coronary-intervention-according-to-clinical-presentation-a-post-hoc-analysis-of-the-randomised-one-month-dapt-trial | - |
dc.contributor.alternativeName | Kim, Byeong Keuk | - |
dc.contributor.affiliatedAuthor | 김병극 | - |
dc.contributor.affiliatedAuthor | 안철민 | - |
dc.contributor.affiliatedAuthor | 이승준 | - |
dc.contributor.affiliatedAuthor | 홍명기 | - |
dc.contributor.affiliatedAuthor | 홍성진 | - |
dc.contributor.affiliatedAuthor | 이용준 | - |
dc.contributor.affiliatedAuthor | 김중선 | - |
dc.contributor.affiliatedAuthor | 고영국 | - |
dc.contributor.affiliatedAuthor | 최동훈 | - |
dc.citation.volume | 18 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 471 | - |
dc.citation.endPage | 481 | - |
dc.identifier.bibliographicCitation | EUROINTERVENTION, Vol.18(6) : 471-481, 2022-08 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.